CERE News and Press, Ceres Inc. From 08/11/21

The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Cerevel Therapeutics Holdings, Inc. 2021 Q2 - Results - Earnings Call Presentation

Announced positive topline results for CVL-231 in Phase 1b trial in schizophrenia Raised $328 million in net proceeds from follow-on offering of common stock and announced redemption of outstanding public warrants Received Fast Track designation and initiated screening i...

CAMBRIDGE, Mass., July 30, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE; CEREW) (the “Company”), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that on August 30, 2021 at 5:00 p.m. ET, it will red...

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report second quarter 2021 financial results and provide a pipelin...

Cerevel Therapeutics (NASDAQ: CERE) closed Monday at $21.39, after starting the year at $15.55, a rise of more than 29% for the first half of 2021. Most of that climb came late last month after the company released positive phase 1B results regarding the use of its CVL-231 antip...

Cerevel Therapeutics was spun out of Pfizer's neurology assets. The company is backed by Bain Capital, among others. The stock went up hugely on positive early stage data. For further details see: Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Matteo Colombo/DigitalVision via Getty Images S&P 500 Health Care Sector Index rose ~2.0% over the week to outpace the ~1.7% gain in the S&P 500 as gene editing companies rallied after Intellia (NTLA) and Regeneron (REGN) showed promise in the CRISPR technology with fir...

Shares of Cerevel Therapeutics ([[CERE]] -13.1%) are sharply down in afternoon trading after the company priced a $350M equity offering of 14M shares are $25 per share.The closing date is July 7.Underwriters have an a 30-day option to purchase an additional 2.1M shares.However, Cerevel shares...

The stock of Cerevel Therapeutics Holdings (NASDAQ: CERE) is under pressure in response to a secondary offering the company priced this morning. Investors unhappy about the dilutive effect of the offering pushed the stock 11.3% lower as of 12:42 p.m. on Friday. On Tuesday, share...

Gainers: Sequential Brands Group (SQBG) +88%.Alector (ALEC) +50%.TAT Technologies (TATT) +43%.Marin Software (MRIN) +41%.Overseas Shipholding (OSG) +35%.Staffing 360 Solutions (STAF) +31%.Bridgeline Digital (BLIN) +31%.IDT (IDT) +21%.Nortech Systems (NSYS) +19%.Ocean Power Technologies (OPTT)...